+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Drugs In Development, 2021

  • ID: 5359582
  • Drug Pipelines
  • June 2021
  • Region: Global
  • 80 pages
  • Global Markets Direct

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Roivant Sciences Ltd
  • Zenith Epigenetics Ltd
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report Bromodomain Containing Protein 3 - Drugs In Development, 2021, outlays comprehensive information on the Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Bromodomain-containing protein 3 (BRD3) or RING3-like protein (RING3L) is a protein that encodes the BRD3 gene. It plays a role in the regulation of transcription, probably by chromatin remodeling and interaction with transcription factors. It regulates transcription by promoting the binding of the transcription factor GATA1 to its targets. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Report covers products from therapy areas Oncology, Dermatology, Immunology and Musculoskeletal Disorders which include indications Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Diffuse Large B-Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Solid Tumor, Atopic Dermatitis (Atopic Eczema), Colorectal Cancer, Melanoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Ovarian Cancer, Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Small-Cell Lung Cancer, Triple-Negative Breast Cancer (TNBC), B-Cell Non-Hodgkin Lymphoma, Basal Cell Carcinoma (Basal Cell Epithelioma), Colon Cancer, Epithelial Ovarian Cancer, Fibrosis, Follicular Lymphoma, Leukemia, Lung Cancer, Lymphoma, Multiple Myeloma (Kahler Disease), Myeloproliferative Disorders, Non-Small Cell Lung Cancer, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Pancreatic Cancer, Primary Mediastinal B-Cell Lymphoma, Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Systemic Sclerosis (Scleroderma) and Unspecified B-Cell Lymphomas.

Furthermore, this report also reviews key players involved in Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3)
  • The report reviews Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) targeted therapeutics
Reasons to Buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3)Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AbbVie Inc
  • Amgen Inc
  • Bristol-Myers Squibb Co
  • Roivant Sciences Ltd
  • Zenith Epigenetics Ltd
Introduction
  • Report Coverage
Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Overview

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Companies Involved in Therapeutics Development
  • AbbVie Inc
  • Amgen Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Constellation Pharmaceuticals Inc
  • Ningbo Wenda Pharmaceutical Technology Co Ltd
  • Roivant Sciences Ltd
  • Zenith Epigenetics Ltd
Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Drug Profiles

ABBV-744 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
BI-894999 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
CC-95775 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
NHWD-870 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
NUE-19796 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
NUE-20798 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
pelabresib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
QCA-570 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Small Molecule to Inhibit BET 3 for Metastatic Castration Resistant Prostate Cancer - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
ZEN-3694 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Dormant Products

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Discontinued Products

Bromodomain Containing Protein 3 (RING3 Like Protein or BRD3) - Product Development Milestones

Featured News & Press Releases
  • Jun 11, 2021: Constellation Pharmaceuticals provides an update from the ongoing MANIFEST study of Pelabresib
  • Jun 11, 2021: Constellation Pharmaceuticals provides an update from the Ongoing MANIFEST study of Pelabresib
  • Mar 15, 2021: Zenith Epigenetics announces dosing of first mCRPC patient with a combination of ZEN-3694 + Merck’s immune check point inhibitor KEYTRUDA
  • Jan 07, 2021: Constellation Pharmaceuticals appoints Brendan Delaney as Chief Commercial Officer
  • Dec 06, 2020: Constellation Pharmaceuticals provides update of MANIFEST study for CPI-0610 at ASH Meeting
  • Nov 23, 2020: Constellation Pharmaceuticals to host analyst / investor event to discuss update of MANIFEST clinical trial for CPI-0610 presented at ASH Meeting
  • Jul 29, 2020: Zenith Epigenetics advances ZEN-3694 in multiple cancer programs
  • Jul 29, 2020: Researchers optimistic after dose-determining trial of compound against metastatic castration-resistant prostate cancer
  • Jun 12, 2020: Constellation Pharmaceuticals provides updates of MANIFEST study for CPI-0610 and EZH2 Franchise
  • May 28, 2020: Constellation Pharmaceuticals to host analyst/investor event to discuss update of MANIFEST clinical trial for CPI-0610
  • May 28, 2020: Constellation Pharmaceuticals to host analyst / investor event to discuss update of MANIFEST clinical trial for CPI-0610
  • May 14, 2020: Constellation Pharmaceuticals provides update of preliminary data for CPI-0610 in three EHA Abstracts
  • Apr 15, 2020: New cancer drug shrinks tumors, reduces side effects, in animal studies
  • Jan 07, 2020: Zenith Epigenetics receives US$5 million milestone payment from Newsoara
  • Dec 19, 2019: Zenith Epigenetics announces clinical advancement of ZEN-3694
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact the Publisher
  • Disclaimer
List of Tables
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Indications, 2021
  • Number of Products under Development by Companies, 2021
  • Products under Development by Companies, 2021
  • Number of Products under Investigation by Universities/Institutes, 2021
  • Products under Investigation by Universities/Institutes, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pipeline by AbbVie Inc, 2021
  • Pipeline by Amgen Inc, 2021
  • Pipeline by Boehringer Ingelheim International GmbH, 2021
  • Pipeline by Bristol-Myers Squibb Co, 2021
  • Pipeline by Constellation Pharmaceuticals Inc, 2021
  • Pipeline by Ningbo Wenda Pharmaceutical Technology Co Ltd, 2021
  • Pipeline by Roivant Sciences Ltd, 2021
  • Pipeline by Zenith Epigenetics Ltd, 2021
  • Dormant Products, 2021
  • Discontinued Products, 2021
List of Figures
  • Number of Products under Development by Stage of Development, 2021
  • Number of Products under Development by Therapy Areas, 2021
  • Number of Products under Development by Top 10 Indications, 2021
  • Number of Products by Stage and Mechanism of Actions, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
Note: Product cover images may vary from those shown
  • AbbVie Inc
  • Amgen Inc
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb Co
  • Constellation Pharmaceuticals Inc
  • Ningbo Wenda Pharmaceutical Technology Co Ltd
  • Roivant Sciences Ltd
  • Zenith Epigenetics Ltd
Note: Product cover images may vary from those shown
Adroll
adroll